1. Celector®: An Innovative Technology for Quality Control of Living Cells
- Author
-
Silvia Zia, Barbara Roda, Alessia Maggio, Pasquale Marrazzo, Valeria Pizzuti, Francesco Alviano, Laura Bonsi, Valentina Marassi, Andrea Zattoni, and Pierluigi Reschiglian
- Subjects
advanced therapy medicinal products ,tumor model ,drug system development ,quality control of cell products ,tag-less cell analysis ,Technology ,Engineering (General). Civil engineering (General) ,TA1-2040 ,Biology (General) ,QH301-705.5 ,Physics ,QC1-999 ,Chemistry ,QD1-999 - Abstract
Among the in vitro and ex vivo models used to study human cancer biology, cancer cell lines are widely utilized. The standardization of a correct tumor model including the stage of in vitro testing would allow for the development of new high-efficiency drug systems. The poor correlation between preclinical in vitro and in vivo data and clinical trials is still an open issue, hence the need for new systems for the quality control (QC) of these cell products. In this work, we present a new technology, Celector®, capable of the label-free analysis and separation of cells based on their physical characteristics with full preservation of their native properties. Two types of cancer cell lines were used: HL60 as cells growing in suspension and SW620 as adherent cells. Cell lines in general show a growth variability depending on the passage and method of culture. Celector® highlights physical differences that can be correlated to cell viability. This work demonstrates the use of Celector® as an analytical platform for the QC of cells used for drug screening, with fundamental improvement of preclinical tests. Cells with a stable doubling time under analysis can be collected and used as standardized systems for high-quality drug monitoring.
- Published
- 2022
- Full Text
- View/download PDF